628
Participants
Start Date
January 29, 2021
Primary Completion Date
September 13, 2023
Study Completion Date
October 11, 2023
Placebo (Cohorts 1 and 2)
4 matching placebo tablets taken twice daily
PF-06882961 (Cohorts 1 and 2)
Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
Placebo (Cohort 3)
2 matching placebo tablets taken twice daily
PF-06882961 (Cohort 3)
Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.
National Cheng Kung University Hospital, Tainan City
PMG Research of Raleigh, LLC, Raleigh
PMG Research of Salisbury, LLC, Salisbury
Accellacare - Wilmington, Wilmington
PMG Research of Hickory, LLC, Hickory
Coastal Carolina Research Center, North Charleston
Clinical Trials of South Carolina, Moncks Corner
Palmetto Clinical Research, Summerville
Palmetto Primary Care Physicians (Sub-I physicals only), Summerville
Clinical Neuroscience Solutions, Inc., Orlando
Optimus U Corporation, Miami
Alliance for Multispecialty Research, LLC, Coral Gables
ForCare Clinical Research, Tampa
Pinnacle Research Group, LLC, Anniston
Internal Medicine and Pediatric Associates of Bristol, PC, Bristol
PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville
Clinical Neuroscience Solutions, Inc., Memphis
L-MARC Research Center, Louisville
China Medical University Hospital, Taichung
Velocity Clinical Research, Inc., Cleveland
Velocity Clinical Research, Valparaiso, Valparaiso
MediSphere Medical Research Center, LLC, Evansville
Lillestol Research LLC, Fargo
Clinical Investigation Specialists, Gurnee
Cotton O'Neil Clinical Research Center, Topeka
Velocity Clinical Research, Omaha, Omaha
Velocity Clinical Research - Westlake, Los Angeles
Anaheim Clinical Trials, LLC, Anaheim
ActivMed Practices & Research, LLC, Methuen
Rivergrove Medical Clinic, Winnipeg
Aggarwal and Associates Limited, Brampton
Milestone Research , Inc, London
Manna Research Toronto, Toronto
Ecogene-21, Chicoutimi
Alpha Recherche Clinique, Québec
Diex Recherche Sherbrooke Inc., Sherbrooke
Centre de Recherche Saint-Louis, Québec
Medical Corporation Heishinkai OCROM Clinic, Suita-shi
Tokyo Center Clinic, Chuo-ku
Fukuwa Clinic, Chuo-ku
Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku
Lead Sponsor
Pfizer
INDUSTRY